Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
A Phase 2 Study of Regorafenib in Metastatic Gastrointestinal Stromal Tumours With C-KIT exon17 Mutation
Sponsor: Chang Gung Memorial Hospital
This PHASE2 trial investigates Gastrointestinal Stromal Tumour (GIST) and is currently completed. Chang Gung Memorial Hospital leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 3 earlier versions
-
Jun 2018 — Apr 2019 [monthly]
Unknown Status PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2017 — Feb 2018 [monthly]
Recruiting PHASE2
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chang Gung Memorial Hospital
For direct contact, visit the study record on ClinicalTrials.gov .